NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company provided an update regarding the appointment of Thomas J. Lynch, Jr., MD, as Chairman of the Board at Kleo Pharmaceuticals. Biohaven's current ownership interest in outstanding stock of Kle

TOKYO and MUNICH and BASKING RIDGE, N.J., Nov. 4, 2019 /PRNewswire/ -- Daiichi Sankyo Co., Ltd announced today that the company has filed a Declaratory Judgement action in the District Court of Delaware in response to receiving communications from Seattle Genetics, Inc

HOUSTON, Nov. 4, 2019 /PRNewswire/ -- Cuddly bears named after Miguel and Bella, children who are being treated at St. Jude, are waiting at your local Stage and

-Transformative acquisition creates global cell and gene therapy manufacturing services platform for both clinical and commercial products -EW Healthcare Partners and its co-investors provide the financing for the transaction MEMPHIS, Tenn., Nov. 4, 2019 /PRNewswire/ -- Cognate BioServices (Cognate), a leading contract development and manufacturi

PARIS, Nov. 4, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years of age and older. Fluzone® High-Dose (Influenza Vaccine) was approved by the FDA in 2009 as a trivalent influenza vaccine, including two inf

DENVER, Nov. 4, 2019 /PRNewswire/ -- Most adults are unprepared or lack confidence to help if a medical emergency occurs, according to a new public poll from the American College of Emergency Physicians (ACEP). And, that confidence wanes as medical emergencies become more serious.

STAINES-UPON-THAMES, United Kingdom, Nov. 4, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it ha

INDIANAPOLIS, Nov. 4, 2019 /PRNewswire/ -- MiraVista Diagnostics, a global leader in diagnostic testing for fungal diseases, has advanced unprecedented growth in 2019. The company's recent expansion efforts include a 27 percent growth in workforce, construction of 24,000 square feet of research and development space, expansion of molecular diagnostic capabilities an

Paul Campanelli Appointed Chairman of the Board, Will Also Continue as President and Chief Executive Officer Until Successor Appointed; Roger Kimmel Appointed Senior Independent Director DUBLIN, Nov. 4, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that Paul V. Campanelli, President and Chi

- Operating Performance Led by Year-over-Year Double-Digit-Percentage Revenue Growth in Sterile Injectables and in Specialty Products Portfolio of Branded Pharmaceuticals -- Full-Year 2019 Financial Guidance Updated to Narrow Expected Ranges for Revenue, Adjusted Diluted Net Income per Share from Continuing Operations and Adjusted EBITDA - DUBLIN, Nov. 4, 2019 /PRNewswir